Current investments
We have one or more companies open for investments. Please login or create an account to learn more and invest.
Completed investments
NEOGAP Therapeutics AB
NEOGAP has a unique approach to train the patient’s immune system to target tumour-specific mutations, so called neoantigens to eradicate the cancer. The treatment has the potential to kill the cancer cells while leaving healthy cells untouched, which significantly reduces the risk of side effects.
SAGA Diagnostics
SAGA Diagnostics develops ultrasensitive liquid biopsy tests for early detection of cancer relapse and personalized cancer treatment. The tests are based on the company’s proprietary technologies for analyzing circulating tumor DNA (ctDNA).
Capitainer
Capitainer supplies intelligent solutions for self-sampling of blood and plasma. The product qDBS is based on DBS (Dried Blood Spot) technology and is designed for easy home sampling of blood with high precision.
Synartro
Synartro is developing a unique treatment for knee osteoarthritis by combining two well-tried drugs, which will offer an effective and safe alternative to today’s treatments.
Exits
Lipigon Pharmaceuticals
Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.
Read more
Liv Diagnostics
Tumor cell proliferation causes 90% of all cancer deaths. Liv Diagnostics is developing new technology to measure the spreading capacity of tumor cells and provide predictive information on the risk of metastasis.
Read more
Raytelligence
Raytelligence has developed a unique, non-intrusive radar sensor and cloud platform for monitoring vital signs, such as respiration, heartbeat and position and movement. The company focuses on elderly care in the home.
Read more